Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PRV-3279
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : Provention Bio
Deal Size : $293.0 million
Deal Type : Collaboration
Details : Provention Bio plans to begin a Phase 2a trial of PRV-3279 in systemic lupus erythematosus (SLE) in the second half of 2021 and expects a portion of such trial to be conducted in China.
Brand Name : PRV-3279
Molecule Type : Large molecule
Upfront Cash : $6.0 million
February 17, 2021
Lead Product(s) : PRV-3279
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : Provention Bio
Deal Size : $293.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
